GLP-1 Research · 17 products
Research-grade GLP-1, GIP, and glucagon receptor agonists for in-vitro laboratory study, including semaglutide, tirzepatide, retatrutide, cagrilintide, and survodutide. Every vial is third-party HPLC and mass-spec tested to 99% purity with a public Certificate of Analysis. For research use only.
In stockGLP-1 Research
Amylin analogue + GLP-1 receptor agonist
In stockGLP-1 Research
Long-acting amylin analogue
In stockGLP-1 Research
Long-acting amylin analogue
In stockGLP-1 Research
Triple incretin receptor agonist
In stockGLP-1 Research
Triple incretin receptor agonist
In stockGLP-1 Research
Triple incretin receptor agonist
In stockGLP-1 Research
Triple incretin receptor agonist
In stockGLP-1 Research
Triple incretin receptor agonist
In stockGLP-1 Research
GLP-1 receptor agonist
In stockGLP-1 Research
GLP-1 receptor agonist
In stockGLP-1 Research
GLP-1 receptor agonist
In stockGLP-1 Research
Dual receptor agonist
In stockGLP-1 Research
Dual incretin receptor agonist
In stockGLP-1 Research
Dual incretin receptor agonist
In stockGLP-1 Research
Dual incretin receptor agonist
In stockGLP-1 Research
Dual incretin receptor agonist
In stockGLP-1 Research
Dual incretin receptor agonist
Compound reference
Amylin analogue + GLP-1 receptor agonist
Target: Amylin, calcitonin and GLP-1 receptors
A combined preparation of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist) in one vial.
Supplied for comparative research on combined amylin and GLP-1 receptor signaling, a combination under active clinical investigation.
Long-acting amylin analogue
Target: Amylin and calcitonin receptors
An acylated, long-acting analogue of the pancreatic hormone amylin that activates amylin and calcitonin receptors.
An investigational compound studied in metabolic research, alone and in combination with semaglutide (the CagriSema combination).
Triple incretin receptor agonist
Target: GIP, GLP-1 and glucagon receptors
A single peptide engineered to activate three receptors at once: GIP, GLP-1 and glucagon. It is one of the first triple agonists in this class.
An investigational compound in late-stage clinical development, widely studied in metabolic and incretin receptor research.
GLP-1 receptor agonist
Target: GLP-1 receptor
A GLP-1 analogue with a fatty-acid side chain that binds albumin, giving it a much longer half-life than native GLP-1.
One of the most studied incretin compounds. The same molecule is an approved prescription medicine; research-grade material is used for receptor and signaling studies.
Dual receptor agonist
Target: Glucagon and GLP-1 receptors
A dual agonist of the glucagon and GLP-1 receptors, designed to combine incretin signaling with glucagon receptor activity.
An investigational compound studied in metabolic and liver research, including models of fatty liver disease.
Dual incretin receptor agonist
Target: GIP and GLP-1 receptors
A 39-amino-acid peptide that activates both GIP and GLP-1 receptors, with a fatty-acid side chain that extends its half-life.
Heavily studied in incretin receptor research. The same molecule is an approved prescription medicine; research-grade material is used for receptor and comparative studies.
Other research areas
All products are for in-vitro laboratory research only. Not for human or animal consumption.